In the BioHarmony Drug Report Database
Cladribine
Leustatin, Mavenclad, Litak (cladribine) is a small molecule pharmaceutical. Cladribine was first approved as Leustatin on 1993-02-26. It is used to treat b-cell chronic lymphocytic leukemia, hairy cell leukemia, multiple sclerosis, and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hairy cell leukemia and multiple sclerosis. Cladribine’s patents are valid until 2026-10-16 (FDA).
Trade Name
|
Litak, Mavenclad |
|---|---|
Common Name
|
cladribine |
ChEMBL ID
|
CHEMBL1619 |
Indication
|
b-cell chronic lymphocytic leukemia, hairy cell leukemia, multiple sclerosis, non-hodgkin lymphoma |
Drug Class
|
Ribofuranil derivatives (pyrazofurin type) |
Image (chem structure or protein)